Download Complete Issue (pdf 3800kb) - Academic Journals

More documents

Recommendations

Info

1916 Afr. J. Pharm. Pharmacol. Table 2. Quality assessment of included RCTs. Study ID Randomization Allocation concealment Double blinding Dropouts\withdraws Jadad Grade Zheng HZ 2010 Yes Unclear Unclear No B Su XD 2010 Yes Unclear Unclear No B Judlin 2010 Adequate Yes Yes Yes A Meng W 2009 Yes Unclear Unclear No B Dang JD 2009 Yes Unclear Unclear No B Wang G 2009(a) Yes Unclear Unclear No B Wang G 2009(b) Yes Unclear Unclear No B Jin X 2009 Yes Unclear Unclear No B Wang X 2009 Yes Unclear Unclear No B Zhang YH 2009 Yes Unclear Unclear No B Heystek 2009 Yes Unclear Yes Yes B Li SQ 2008 Yes Unclear Unclear No B Pei YH 2008 Yes Unclear Unclear No B Zhang GH 2007 Yes Unclear Unclear No B Sun GQ 2007 Yes Unclear Unclear Yes B Ross 2006 Yes Unclear Yes Yes B Luo XM 2006 Yes Unclear Unclear No B Luo JL 2006 Yes Unclear Unclear No B Gao HY 2005 Adequate Unclear Yes Yes B Tian YP 2005 Yes Unclear Unclear No B Zhang WF 2004 Yes Unclear Unclear No B Cai SF 2003 Adequate Unclear Yes No B (sparfloxacin and gatifloxacin have been withdrawn from the American market, respectively, in 2005 due to QT prolongation and in 2006 due to dysglycemia). All patients included in the meta-analysis received antimicrobial treatment for a period of no less than seven days and a maximum of fourteen days. The quality assessment of included RCTs is presented in Table 2. There studies clarified adequate randomization procedures, one reported allocation concealment, five used double blinding and five reported numbers of dropouts\withdrawals. One were eventually assessed to be good in terms of methodology with a Jadad score A (Juni et al., 2001), the other twenty-one were B. Comparisons of effectiveness Clinical success All the twenty-two studies provided specific data for analysis of clinical cure. Clinical cure rate in the moxifloxacin group [1513 (77.7%) of 1947 patients] was higher than control group [1370 (72.91%) of 1879 patients], whilst statistically significant difference was found [RR = 1.08, 95%CI (1.02, 1.14), P = 0.008] (Figure 2). 19 studies (Zheng, 2010; Su et al., 2010; Meng et al., 2009; Tang et al., 2009; Wang et al., 2009a; Wang et al., 2009b; Jin et al., 2009; Wang et al., 2009; Zhang et al., 2009; Li, 2008; Per et al., 2009; Zhang et al., 2007; Sun, 2007; Luo et al., 2006; Luo et al., 2006; Gao et al., 2005; Tian et al., 2005; Zhang et al., 2004; Cai et al., 2003) provided relevant data for analysis of clinical effectiveness which consisted of clinical cure and improvement. Clinical effective rate in the moxifloxacin group [1156 (92.9%) of 1244 patients] was higher than the control group [1035 (85.0%) of 1217 patients], while statistically significant difference was found [RR = 1.09, 95%CI (1.04, 1.14), P = 0.0005] (Figure 3). Microbiological treatment success 17 (Judin et al., 2010; Tang et al., 2009; Wang et al., 2009a; Wang et al., 2009b; Jin et al., 2009; Zhang et al., 2009; Heystek and Ross., 2009; Li, 2008; Per et al., 2009; Zhang et al., 2007; Sun, 2007; Ross et al., 2006; Luo JL et al., 2006; Gao et al., 2005; Tian et al., 2005; Zhang et al., 2004; Cai et al., 2003) of the 22 RCTs provided microbiological eradication data. 1088 (90.8%) of the 1198 patients in the moxifloxacin group and 1001 (86.5%) of the 1157 patients in the control group achieved eradication of the baseline pathogens. The overall pathogens eradication rate in the moxifloxacin group (90.8%, 1088/1198) was higher than control group
Study or Subgroup Cai SF 2003 Gao HY 2005 Heystek2009 Jin X 2009 Judlin 2010 Li SQ 2008 Luo JL 2006(1) Luo JL 2006(2) Luo XM 2006 Meng W 2009 Pei YH 2008 Ross2006 Su XD 2010 Sun GQ 2007 Tang JD 2009 Tian YP2005 Wang G2009 (a1) Wang G2009 (a2) Wang G2009 (b) Wang X2009 Zhang GH 2007 Zhang WF 2004(1) Zhang WF 2004(2) Zhang YH 2009 Zheng HZ 2010 Total (95% CI) Total events Heterogeneity: Tau² = 0.01; Chi² = 67.49, df = 24 (P < 0.00001); I² = 64% Test for overall effect: Z = 2.67 (P = 0.008) moxifloxacin conventional therapy Risk Ratio Risk Ratio Events 18 10 224 113 152 85 34 34 44 23 41 248 24 33 43 23 45 45 90 38 23 32 32 35 24 1513 Total 20 19 232 121 194 90 52 52 56 25 62 275 60 44 50 29 80 80 150 60 38 43 43 40 32 1947 Events 17 8 198 112 155 74 32 20 29 20 20 262 20 12 42 17 44 46 84 29 24 28 23 34 20 1370 Total 20 17 202 121 190 86 50 48 56 25 31 289 60 41 50 29 80 80 149 60 38 43 43 40 31 1879 Weight 3.7% 0.7% 10.1% 9.0% 7.9% 7.9% 2.8% 1.7% 2.8% 3.8% 2.4% 9.6% 1.2% 1.1% 5.5% 2.0% 3.0% 3.1% 4.7% 2.3% 2.0% 2.9% 2.3% 5.2% 2.3% 100.0% M-H, Random, 95% CI 1.06 [0.84, 1.34] 1.12 [0.58, 2.16] 0.99 [0.95, 1.02] 1.01 [0.94, 1.08] 0.96 [0.87, 1.06] 1.10 [0.99, 1.21] 1.02 [0.77, 1.36] 1.57 [1.06, 2.31] 1.52 [1.14, 2.02] 1.15 [0.92, 1.44] 1.02 [0.75, 1.41] 0.99 [0.94, 1.05] 1.20 [0.75, 1.93] 2.56 [1.55, 4.25] 1.02 [0.87, 1.21] 1.35 [0.95, 1.94] 1.02 [0.78, 1.35] 0.98 [0.75, 1.28] 1.06 [0.88, 1.29] 1.31 [0.95, 1.81] 0.96 [0.67, 1.36] 1.14 [0.86, 1.51] 1.39 [1.00, 1.93] 1.03 [0.86, 1.23] 1.16 [0.84, 1.62] 1.08 [1.02, 1.14] Figure 2. Meta-analysis of cure rates of moxifloxacin and conventional therapy. Study or Subgroup Cai SF 2003 Gao HY 2005 Jin X 2009 Li SQ 2008 Luo JL 2006(1) Luo JL 2006(2) Luo XM 2006 Meng W 2009 Pei YH 2008 Su XD 2010 Sun GQ 2007 Tang JD 2009 Tian YP2005 Wang G2009 (a1) Wang G2009 (a2) Wang G2009 (b) Wang X2009 Zhang GH 2007 Zhang WF 2004(1) Zhang WF 2004(2) Zhang YH 2009 Zheng HZ 2010 Total (95% CI) Total events Heterogeneity: Tau² = 0.01; Chi² = 68.35, df = 21 (P < 0.00001); I² = 69% Test for overall effect: Z = 3.46 (P = 0.0005) M-H, Random, 95% CI 0.5 0.7 1 1.5 2 Favours conventional Favours moxifloxacin moxifloxacin conventional therapy Risk Ratio Risk Ratio Events 19 16 115 88 48 48 51 25 57 54 41 46 27 73 73 144 49 33 41 41 38 29 1156 Total 20 19 121 90 51 51 56 25 62 60 44 50 29 80 80 150 60 38 43 43 40 32 1244 Events 18 14 116 79 45 31 43 24 31 43 31 45 19 73 75 142 39 34 39 30 37 27 1035 Total 20 17 121 86 50 48 56 25 50 60 41 50 29 80 80 149 60 38 43 43 40 31 1217 Weight 3.8% 2.0% 7.2% 6.8% 5.5% 3.0% 4.1% 5.6% 2.8% 3.7% 3.5% 5.2% 2.1% 6.0% 6.3% 7.4% 2.9% 4.1% 5.4% 3.2% 5.5% 3.8% 100.0% M-H, Random, 95% CI 1.06 [0.88, 1.26] 1.02 [0.76, 1.37] 0.99 [0.94, 1.05] 1.06 [0.99, 1.14] 1.05 [0.93, 1.17] 1.46 [1.17, 1.82] 1.19 [1.00, 1.40] 1.04 [0.93, 1.16] 1.48 [1.18, 1.86] 1.26 [1.05, 1.50] 1.23 [1.02, 1.49] 1.02 [0.90, 1.16] 1.42 [1.07, 1.88] 1.00 [0.91, 1.10] 0.97 [0.89, 1.06] 1.01 [0.96, 1.06] 1.26 [1.01, 1.57] 0.97 [0.82, 1.14] 1.05 [0.94, 1.18] 1.37 [1.11, 1.68] 1.03 [0.92, 1.15] 1.04 [0.87, 1.24] 1.09 [1.04, 1.14] Figure 3. Meta-analysis of clinical effective rates of moxifloxacin and conventional therapy. M-H, Random, 95% CI 0.5 0.7 1 1.5 2 Favours conventional Favours moxifloxacin Mu et al. 1917
Page 1 and 2: African Journal of Pharmacy and Pha
Page 3 and 4: Editors Sharmilah Pamela Seetulsing
Page 5 and 6: Electronic submission of manuscript
Page 7 and 8: Fees and Charges: Authors are requi
Page 9 and 10: Table of Contents: Volume 6 Number
Page 13 and 14: Minimum inhibitory concentration (M
Page 15 and 16: Kim et al. 1887 Table 4. Antimicrob
Page 17 and 18: Klevens RM, Morrison M A, Nadle J,
Page 19 and 20: Figure 1. Chemical structure of ten
Page 21 and 22: ng/ml by 4.9 ml blank plasma with 5
Page 23 and 24: Figure 5. Chromatogram of plasma sp
Page 25 and 26: Figure 7. Chromatogram of a healthy
Page 27 and 28: Figure 11. Chromatograms of standar
Page 31 and 32: Shatoor 1903 Figure 1. The effect o
Page 33 and 34: Heart rate (Beats/min.) 345 330 315
Page 35 and 36: Table 2. Percent of changes in hear
Page 37 and 38: heart rate on coronary flow and car
Page 39 and 40: Urinary tract infections are the mo
Page 41 and 42: Table 1. Study characteristics of i
Page 43: Table 1. contd. Sun GQ 37 007 Ross
Page 47 and 48: Study or Subgroup Cai SF 2003 Gao H
Page 49 and 50: cure rate and clinical effective ra
Page 53 and 54: Table 1. The expression of KAI1 and
Page 57 and 58: Figure 2. Typical chromatograms of
Page 59 and 60: Excretion studies Figure 4 shows th
Page 63 and 64: Table 1. Statistical results of the
Page 65 and 66: ethinylestradiol /100 g levonorgest
Page 67 and 68: HO CH 2OH O OH OH OCH 2CH 2 OH Figu
Page 69 and 70: A B Figure 3. Bax positive cells of
Page 73 and 74: Table 1. Summary of specific reacti
Page 75 and 76: Figure 3. Effects of the sap of Jat
Page 79 and 80: Figure 1. A schematic diagram showi
Page 81 and 82: Chen et al. 1953 Figure 4. Concentr
Page 83 and 84: Figure 6. Representative photomicro
Page 85 and 86: shock. The features of PHC can expl
Page 87 and 88: Administration of single or repeate
Page 89 and 90: Table 1. Effects of green tea on SO
Page 91 and 92: Ozardali I, Bitiren M, Ali ZK, Zeri
Page 93 and 94: EXPERIMENTAL PROCEDURE Materials an
Page 95 and 96:
Scavenging rate (%) Figure 1 Scaven
Page 97 and 98:
A D Figure 5 Figure Effects 5. of E
Page 99 and 100:
African Journal of Pharmacy and Pha
Page 101 and 102:
Figure 1. Level-spacing distributio
Page 103 and 104:
Number of cases Pattern Shi et al.
Page 105 and 106:
Page 107 and 108:
sodium was then dissolved in 1000 m
Page 109 and 110:
Concentration (ppm) Concentration (
Page 111 and 112:
various contagious diseases such as
Page 113 and 114:
Table 3. Antibacterial MIC (µg/ml)
Page 115 and 116:
Table 5. Contd. 1/5 14.7 ± 0.6 39.
Page 117 and 118:
UPCOMING CONFERENCES 6th European C
Page 119:
show all

Download Complete Issue (pdf 3800kb) - Academic Journals

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?